DeoBioSciences is developing a treatment against advanced metastatic cancer for people and pets.
Jan 26, 2022
Jan 26, 2022
DeoBioSciences (DBS) is a stealth mode, R&D stage, virtual biotech developing a cancer drug, based on a naturally occurring compound, that selectively kills both early and advanced stage cancer cells from humans and, potentially, dogs and cats as well.We are reverse engineering the drug from anecdotal data and reports of human efficacy and safety from bioprospecting sources and also corroborating studies involving molecular homologues in humans and animals that further affirmed safety and efficacy projections. So far, our pre-clinical lab results have corroborated and met all our predictions for safety and performance.
Human Cancer MarketIn the U.S. alone, over 1.8 million new cancer cases are diagnosed annually. It is the second leading cause of death. Over 606,000 Americans die of cancer annually, more than 1600 each day in America. (American Cancer Society).The International Agency for Research on Cancer (IARC) roughly estimates that seventeen million (17,000,000) new cases were diagnosed globally in 2020. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths as a result of growth and aging of the population. (American Cancer Society, Global Cancer Facts & Figures.)Pet Cancer MarketCanine cancer is a leading killer of companion dogs in the U.S. According to the Pet Food Institute, the U.S. has over 67 million pet dogs, and the lifetime incidence of canine cancer is approximately 1 in 3, about the same as humans. According to the Comparative Oncology Program of the U.S. National Cancer Institute, approximately 6 million new cancer diagnoses are made in dogs and the same number made in cats each year.
DeoBioSciences has developed an experimental cancer drug (DBX-31) that is a powerful natural compound against cancer.